Self-assessment · 4 minutes
Weight loss & GLP-1 candidacy screener
Answer 8 questions about your weight, prior attempts and metabolic health. We'll show you whether medication, surgery, or lifestyle support is the most evidence-based next step — and what a workup at a Class A hospital in China would cost.
Your height
Educational tool — not a diagnosis. Adapted from NICE NG246 (obesity), ADA Standards of Care 2025, and AACE obesity practice guidelines. Educational screening only.
Frequently asked
Plain-language answers about weight loss, this screener, and what evaluation costs at a Class A hospital in China.
- Am I a candidate for GLP-1 medication like Wegovy or Mounjaro?
- International guidelines (NICE NG246, ADA, AACE) typically recommend GLP-1 receptor agonists for adults with BMI ≥ 30, or BMI ≥ 27 with at least one obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, fatty liver). A pre-treatment endocrinology workup is essential before starting therapy.
- What does a GLP-1 workup at a Class A hospital in China cost?
- Pre-treatment workup plus first prescription is typically $400–600 all-in. Maintenance semaglutide or tirzepatide is $260–320/month from a hospital pharmacy, versus $1,000–1,400/month in the United States. Cost varies by hospital tier and dose.
- Should I try medication before surgery?
- For BMI under 35 without significant comorbidity, medication is the usual first step. For BMI ≥ 35 with comorbidity or BMI ≥ 40, bariatric surgery has the strongest long-term durability evidence — though many patients still trial GLP-1 first.
- Is this self-assessment a diagnosis?
- No. This is an educational screening tool. A positive result indicates that an evaluation by a senior endocrinologist or bariatric surgeon is worthwhile — it does not confirm any diagnosis or prescribe any treatment.
About this screener
Adapted from NICE NG246 (obesity), ADA Standards of Care 2025, and AACE obesity practice guidelines. Educational screening only.
What this screener covers
- Obesity(ICD-10 E66)
- Overweight(ICD-10 E66.3)
- Type 2 diabetes mellitus(ICD-10 E11)
Validated source
Medical review
Reviewed by Panda Touring Care medical team (Endocrinology coordinator review) · Independent — partner Class A hospitals · last reviewed 2025-04-01
Other self-assessments
Adult ADHD self-screener (ASRS-v1.1)
The 6-item Part A of the WHO Adult ADHD Self-Report Scale. Validated screen for adults 18+. Not a diagnosis — but a strong indicator of whether a full evaluation is warranted.
Psychiatry · Mental healthDepression screener (PHQ-9)
The 9-item Patient Health Questionnaire — the most widely used validated depression screener in primary care worldwide. Free, 3 minutes, immediate results.
Psychiatry · Mental healthAnxiety screener (GAD-7)
The 7-item Generalised Anxiety Disorder scale — the standard validated screener for adult anxiety. Free, 2 minutes.
Hepatology · Addiction medicineAlcohol use screener (AUDIT-C)
Three-question alcohol use screener used by the WHO and US Veterans Affairs. Identifies hazardous drinking patterns in under a minute.
Sleep medicineInsomnia severity index (ISI)
Validated 7-item insomnia severity scale. Identifies clinically significant insomnia and tracks treatment response.
Sleep medicine · ENTSleep apnoea risk (STOP-Bang)
Eight yes/no questions used pre-operatively worldwide to predict obstructive sleep apnoea risk. Validated and widely cited.